Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment | Latest News RSS feed

Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment - Latest News


Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment

Mirati is a gift that keeps on giving, as the company logged astronomical profits for shareholders. Powered by a broad and high-quality pipeline, there are more “shots on goal” of finding a blockbuste... read more

MD Anderson and Accelerator Life Science Partners launch Magnolia Neurosciences

The University of Texas MD Anderson Cancer ... Therapeutics Discovery division is a unique group of more than 100 clinicians, researchers and drug discovery scientists at MD Anderson working to develo... read more

Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development

May 24, 2018 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer ... as th... read more

Looking for another news?


Dr. Emil Frei III Establishes a New Cancer Services Platform

His plan will provide for a stronger and more consistent approach to the development of drugs and most therapeutic biologics used to diagnose, treat, and prevent cancer. Molecular science by identifyi... read more


10 Top Stock Ideas to Beat the Blues

And don’t let the recent departure of the company’s chief of product innovation ... Therapeutics (NASDAQ:MGEN) is a tiny clinical-stage biotech developing microRNA-based therapies for cancer and other ... read more

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

If approved, EM-100 would be the first topical, preservative-free formulation for the treatment... Mirati Therapeutics ... with Moores Cancer... Alkahest Inc. ("Alkahest"), a clinical-stage biotechnol... read more

MIRATI THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

On August 2, 2018, the Company entered into a Third Amendment to Lease Agreement (the "Amendment") with ARE-SD Region No. 20 (the "Landlord") to amend the Lease Agreement, dated June 24, 2014, the Fir... read more

MD Anderson and Accelerator Life Science Partners launch Magnolia Neurosciences to speed development of neuroprotective therapies

Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center and ... Anderson working to develop innovative treatment options, including small molecules, biologics and cell-based therapies. ... read more

BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region

BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, and Mirati Therapeu... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us